Trial reportJournal of neuro-oncology2019
Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.
Trial report in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Characteristics of [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.Journal of neuro-oncology · 2025Article
- Freiburg Neuropathology Case Conference: Transition from Chronic Dizziness to Acute Headache and Nausea in a 30-Year-Old.Clinical neuroradiology · 2025Article
- Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.Journal of neuro-oncology · 2025Article
- Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.European radiology · 2025Article
- The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Neuro-oncology · 2024Review
- Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma.Biomolecules & biomedicine · 2023Article
- Epidemiology and risk stratification of low-grade gliomas in the United States, 2004-2019: A competing-risk regression model for survival analysis.Frontiers in oncology · 2023Article
- Conventional MRI-Derived Biomarkers of Adult-Type Diffuse Glioma Molecular Subtypes: A Comprehensive Review.Biomedicines · 2022Review
- Preoperative imaging features: Are they useful tools for predicting IDH1 mutation status in gliomas Grades II-IV?Surgical neurology international · 2022Article
- CombiningJournal of neuro-oncology · 2021Article
- Article
- Additive Value of Dynamic FDOPA PET/CT for Glioma Grading.Frontiers in medicine · 2021Article
- Establishment of age group classification for risk stratification in glioma patients.BMC neurology · 2020Article
- Evaluation of glial tumors: correlation between magnetic resonance imaging and histopathological analysis.Radiologia brasileiraArticle
- Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis.Neuro-oncology advancesReview
- Disturbance of functional connectivity in patients with low grade glioma is associated with worse progression-free survival.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast enhancement (CE) is found in 10-60% of low-grade gliomas. Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is elusive. The aim of this study is to investigate whether CE is associated with molecular characteristics of low-grade gliomas and uncover its prognostic value. MATERIALS AND
methodsAll confirmed histological cases of low-grade gliomas diagnosed at our institution between years 2000-2016 were reviewed (n = 102). Spinal and brainstem localization, only-biopsied tumours with ring-like enhancement and incomplete medical records were excluded.
resultsMean age was 42 years ( ± 13.9 years), and 63.6% were male. The median follow-up time was 79.8 months. CE was present on 25% of preoperative MRI, and 25% of patients were considered high-risk according to Pignatti score. Most were astrocytomas (67%) and 87.2% were surgically removed. IDH mutation was found in 64.6% of tumour samples, and 18.8% had a 1p/19q codeletion. No subgroup differences were observed according to CE except for presurgical performance status and postoperative chemotherapy. IDH status and 1p/19q codeletion were evenly distributed. On univariate analysis, age, size > 6 cm, CE, extent of resection, Pignatti score, IDH mutation and 1p/19q codeletion were significantly associated to OS. On multivariate analysis, only CE and IDH status were independently associated to OS. CE remained a significant prognostic factor in IDH-mutant non-codeleted tumours when analysed by tumour subtype.
conclusionCE in low-grade gliomas provides prognostic information in IDH-mutant non-codeleted tumours, although its meaning remains uncertain in IDH-wildtype gliomas.
Indexed as
Identifiers
31054099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.